Weight Loss

What to Look for in a Protein Powder?

Besides a balanced diet, many individuals opt to include supplements as part of their daily food intake. Protein powder is one such supplement which has become increasingly popular over recent years, with many users who want to achieve weight loss and muscle growth.

Unexplained Weight Loss: When It Might Signal a Health Problem

Is Cottage Cheese Good for Weight Loss? Evidence from Clinical Studies

The Natural Molecule That Could Rival Ozempic

Circadian Rhythm and Weight Loss

Wegovy: A Breakthrough in Weight Loss?

Is a Hypocaloric Diet Safe and Effective for Long-Term Health?

Vegetarian Diets for Weight Loss

Weight Loss After Bariatric Surgery

Who Should Take Weight Loss Injections, and Who Shouldn’t?

Semaglutide and Weight Loss in Menopause

What's Next for Semaglutide? Beyond Diabetes and Weight Loss

See more featured articles »

Cachexia and Cancer

Does Cinnamon Help with Weight Loss?

How Oral GLP-1 Drugs Work For Weight Loss

Oral GLP-1 Pills for Weight Loss: How Orforglipron Works

Cachexia / Wasting Syndrome

How Does Semaglutide Work to Lose Weight?

What Is Cancer Cachexia? Causes, Symptoms, Diagnosis, and Treatment

Military Diet: Health Risks

GLP-1 and Diet: Evidence-Based Strategies for Better Weight Loss

Mental Health Disorders, Weight Gain, and Exercise

Latest Weight Loss News and Research

GLP-1 medicines may cut clot-related risks in chronically inflamed patients

In a target trial emulation using OneFlorida+ electronic health record data, GLP-1 receptor agonist use in adults with obesity and autoimmune disease was linked to lower hazards of pulmonary embolism, venous thromboembolism, stroke/TIA, emergency department visits, and all-cause mortality.

10 Jun 2026

Injectable semaglutide may improve fertility outcomes in PMOS

Researchers at the University of Colorado Anschutz have published a proof-of-concept study in Fertility and Sterility demonstrating that injectable semaglutide may offer meaningful reproductive benefits for women with polyendocrine metabolic ovarian syndrome (PMOS), formerly known as polycystic ovary syndrome (PCOS).

9 Jun 2026

Apitegromab helps tirzepatide users lose fat while preserving lean mass

A phase 2 trial found that apitegromab plus tirzepatide reduced lean body mass loss by 1.9 kg compared with tirzepatide plus placebo after 24 weeks, while overall weight loss remained similar.

9 Jun 2026

Obesity drug mazdutide reduces weight and waist size in major trial

Once-weekly 9 mg mazdutide produced clinically meaningful weight loss in Chinese adults with obesity, reducing body weight by 16.65% after 60 weeks versus 1.50% with placebo. The phase 3 GLORY-2 trial also found improvements in waist circumference, systolic blood pressure, and lipid markers, but gastrointestinal adverse events were common.

9 Jun 2026

$Study reveals main risks for fractures and senior falls$

Study reveals main risks for fractures and senior falls

With an aging population now the irrefutable reality in Japan, concerns around the health and wellbeing of older adults have come to the forefront of public health dialogues.

9 Jun 2026

GLP-1 users say the drugs quiet food noise but do not replace lifestyle change

A qualitative study of 30 US adults found that GLP-1 receptor agonists often reduced “food noise,” psychological hunger, and appetite, helping patients feel more able to make deliberate lifestyle changes.

8 Jun 2026

Blocking immune pathway slows Huntington disease in mouse models

Huntington disease is a rare, inherited brain disorder that progressively destroys nerve cells, leading to worsening movement, cognitive and psychiatric symptoms.

8 Jun 2026

Expert review examines widely-held beliefs about dietary protein needs and benefits

A newly published peer-reviewed paper in Critical Reviews in Food Science and Nutrition synthesizes findings from a February 2025 scientific workshop.

8 Jun 2026

Weight loss drugs linked to lower risk of alcohol, opioid, nicotine and cocaine use disorders

A new study led by researchers at The University of Texas at El Paso found that use of weight loss drugs like Ozempic and other GLP-1s is associated with a lower risk of developing alcohol, opioid, nicotine and cocaine use disorders.

8 Jun 2026

Weight loss medications show promise in preventing obesity-related cancers

A study of more than 229,000 obese adults without diabetes in the United States has shown that weight loss drugs are associated with a decreased risk of obesity-related cancers.

7 Jun 2026

GLP-1 therapies linked to fewer complications in adults with both obesity and autoimmune disease

Among adults with both obesity and an autoimmune disease, those taking a glucagon-like peptide-receptor 1 agonist (GLP-1RA) medication had lower rates of emergency department visits and were less likely to experience serious cardiac events, such as stroke, pulmonary embolism or death when compared to similar adults who were not taking these medications, according to new research published today in the Journal of the American Heart Association, an open-access, peer-reviewed journal of the American Heart Association.

7 Jun 2026

Biopsy-driven treatment strategy improves clinical outcomes in psoriatic arthritis

The management of psoriatic arthritis is increasingly focused on the early identification of clinical, immunological, and tissue-based phenotypes predictive of therapeutic response.

5 Jun 2026

Sustained weight loss reduces risk of future atrial fibrillation

Announcing a new article publication for Cardiovascular Innovations and Applications journal. The long-term effects of sustained weight gain and loss on atrial fibrillation (AF) risk remain unclear.

4 Jun 2026

Why exercise matters for obesity even when the scale barely moves

AHA's scientific statement reveals exercise's vital role in obesity management, boosting cardiovascular health and supporting long-term weight loss efforts.

4 Jun 2026

Real-world study exposes suboptimal adherence to treat-to-target rheumatic strategies

EULAR - The European Alliance of Associations for Rheumatology - acknowledges the role of diverse real-world data to complement knowledge from randomized controlled trials.

4 Jun 2026

Could GLP-1 drugs help prevent breast cancer? New study points to a possible link

A large retrospective cohort study of 111,646 overweight or obese women found that GLP-1 agonist exposure was associated with lower breast cancer incidence. After propensity-score matching, GLP-1 exposure was linked to nearly 30% lower odds of breast cancer, but the authors stress that randomized trials are needed before these drugs can be considered for prevention.

3 Jun 2026

Continuing gout therapy during remission lowers future flare risk

The European Alliance of Associations for Rheumatology - held its 2026 annual Congress in London, where gout was high on the agenda.

3 Jun 2026

Ketogenic diet shows promise in treating anorexia nervosa

A pilot study published today in Communications Medicine demonstrates the potential of a new approach to treating anorexia nervosa - a disorder for which effective treatments have been significantly limited.

3 Jun 2026

GLP-1 treatments may reduce knee replacement surgery rates

GLP-1 receptor agonist drugs, used for the treatment of diabetes, and more recently, weight loss, are associated with a significantly lower long term risk of knee replacement surgery as a result of osteoarthritis, finds an analysis of medical records data, published in the open access journal Regional Anesthesia & Pain Medicine.

2 Jun 2026

Three-drug strategy forces pancreatic tumors into lasting regression

A triple-targeted preclinical therapy combining daraxonrasib, afatinib, and SD36 drove durable pancreatic cancer regression by blocking KRAS/RAS, EGFR/HER2, and STAT3 signaling. The approach prevented treatment resistance across mouse and human tumor-derived models, but remains preclinical and requires more clinically suitable drug combinations before human testing.

2 Jun 2026